City’s largest share sale in four years shows Beijing’s determination to push China’s EV technologies worldwide, analysts say ...

Chinese drug developer and producer Jiangsu Hengrui Pharmaceuticals is seeking to raise up to HK$9.89 billion ($1.27 billion) in a Hong Kong listing, according to a regulatory filing made on Thursday.

(Reuters) -Chinese battery manufacturer CATL aims to raise about HK$31.01 billion ($3.99 billion) in its Hong Kong listing, ...

Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Shares of Chinese battery giant Contemporary Amperex Technology (CATL) surged as much as 3.43% on the Shenzhen Exchange on ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.

U.S. futures surged after the U.S. and China announced they were suspending for 90 days most of the sharp tariff hikes each ...

Chinese battery manufacturer CATL - or Contemporary Amperex Technology - on Monday started taking investor orders for its $4B ...

CATL's shares will start trading on the Hong Kong Stock Exchange on May 20. CLOSE EYE ON US-CHINA TRADE WAR U.S. onshore investors will not be able to buy CATL shares in the Hong Kong deal ...

Some of China ... thrown off U.S. exchanges. After years of negotiations, China in 2022 agreed to let U.S. regulators review auditing documents in the Chinese city of Hong Kong, lifting the ...